title: [Antibiotic resistance among E. coli isolates from urinary tract infections (1999-2000): a multicenter study].
abstract: E. coli is the most frequently isolate species in community as well as in nosocomial acquired urinary tract infections (UTI). Trimethoprim-sulfamethoxazole (TMP-SMX), is commonly used as empiric treatment for managing uncomplicated UTI whereas the rate of resistance to amoxicilline is increasing. A multicentric retrospective study was conducted from January 1st 1999 to December 31st 2000 to evaluate the prevalence of E. coli isolates from UTI and to guide empiric therapies. Among 6994 urinary isolates, 62.6% were resistant to amoxicilline, this rate fell to 33.6% when amoxicilline was associated to clavulanic acide, 2.7% were producing extended spectrum b-lactamases (BLSE), higher than reported in France and USA. 37.3% were resistant to TMP-SMX. The high prevalence of antimicrobial resistance among UTI E. coli isolates emphasizes the necessity to review the empiric therapies. Fluoroquinolones can be considered as an alternative therapy according to their excellent tissue penetration and their wide spectrum of activity.
authors.affiliation: Laboratoire Résistance aux antibiotiques-Faculté de Médecine, Tunis.
authors.forename: Hanène
authors.initials: H
authors.lastname: Smaoui
authors.forename: Faouzia
authors.initials: F
authors.lastname: Mahjoubi
authors.forename: Ilhem
authors.initials: I
authors.lastname: Boutiba
authors.forename: Wafa
authors.initials: W
authors.lastname: Jouaihia
authors.forename: Lamia
authors.initials: L
authors.lastname: Thabet
authors.forename: Abir
authors.initials: A
authors.lastname: Znazen
authors.forename: Aouatef
authors.initials: A
authors.lastname: Kammoun
authors.forename: Senda
authors.initials: S
authors.lastname: Mezghanni
authors.forename: Ouahid
authors.initials: O
authors.lastname: Triki
authors.forename: Adnène
authors.initials: A
authors.lastname: Hammami
authors.forename: Assia
authors.initials: A
authors.lastname: Ben Hassen
authors.forename: Amel
authors.initials: A
authors.lastname: Kechrid
authors.forename: Saida
authors.initials: S
authors.lastname: Ben Redjeb
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy*; D006801:Humans; D012189:Retrospective Studies; D014416:Tunisia; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents